(VIANEWS) – Shares of ERYTECH PHARMA (CAC 40: ERYP.PA) rose by a staggering 32.18% to €1.07 at 11:51 EST on Tuesday, after two sequential sessions in a row of gains. CAC 40 is falling 0.6% to €7,396.31, after two sequential sessions in a row of gains. This seems, as yet, a somewhat down trend exchanging session today.
ERYTECH PHARMA’s last close was €0.81, 45.17% below its 52-week high of €1.48.
About ERYTECH PHARMA
ERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.
Earnings Per Share
As for profitability, ERYTECH PHARMA has a trailing twelve months EPS of €-0.01.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -0.98%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ERYTECH PHARMA’s stock is considered to be oversold (<=20).
Volatility
ERYTECH PHARMA’s last week, last month’s, and last quarter’s current intraday variation average was a positive 2.57%, a negative 0.11%, and a positive 4.01%.
ERYTECH PHARMA’s highest amplitude of average volatility was 5.50% (last week), 3.07% (last month), and 4.01% (last quarter).
Earnings Before Interest, Taxes, Depreciation, and Amortization
ERYTECH PHARMA’s EBITDA is -12.58.
Volume
Today’s last reported volume for ERYTECH PHARMA is 1235369 which is 455.6% above its average volume of 222348.
More news about ERYTECH PHARMA (ERYP.PA).
